RecruitingNot applicableNCT04055220

Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas

Studying Angiosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centre Leon Berard
Principal Investigator
Jean-Yves BLAY
Centre Léon Bérard, Lyon
Intervention
Treatment by Regorafenib(drug)
Enrollment
168 enrolled
Eligibility
12 years · All sexes
Timeline
2020 – 2026

Study locations (16)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04055220 on ClinicalTrials.gov

Other trials for Angiosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Angiosarcoma →

← Back to all trials